Stockscreener 앱 받기
3.40
3.41%
-0.12
전일 마감가:
$3.52
열려 있는:
$3.41
하루 거래량:
114.42K
Relative Volume:
0.75
시가총액:
$192.99M
수익:
-
순이익/손실:
$-66.86M
주가수익비율:
-2.8333
EPS:
-1.2
순현금흐름:
$-58.82M
1주 성능:
-19.24%
1개월 성능:
-32.54%
6개월 성능:
-32.00%
1년 성능:
-4.49%
1일 변동 폭
$3.295
$3.6588
1주일 범위
$3.295
$4.15
52주 변동 폭
$3.15
$7.77
디자인 테라 Stock (DSGN) Company Profile
명칭
Design Therapeutics Inc
전화
858-293-4900
주소
6005 HIDDEN VALLEY ROAD, CARLSBAD
DSGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
3.40 | 192.99M | 0 | -66.86M | -58.82M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
디자인 테라 Stock (DSGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-07 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-05-04 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-06-10 | 개시 | Wedbush | Outperform |
| 2022-05-02 | 개시 | RBC Capital Mkts | Outperform |
| 2022-01-19 | 개시 | Goldman | Sell |
| 2021-04-20 | 개시 | Goldman | Neutral |
| 2021-04-20 | 개시 | Piper Sandler | Overweight |
| 2021-04-20 | 개시 | SVB Leerink | Outperform |
모두보기
디자인 테라 주식(DSGN)의 최신 뉴스
BlossomHill Therapeutics to Present the Design and Discovery of BH-30643, the Company’s OMNI-EGFR™ Inhibitor, at the 2025 AACR Annual Meeting - BioSpace
Charles Schwab Investment Management Inc. Has $1.63 Million Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
New Clinical Trial Details: Gain's Innovative Parkinson's Treatment Heads to Major Conference - Stock Titan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Bank of New York Mellon Corp Sells 3,777 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Wall Street Analysts See a 31.33% Upside in Design Therapeutics (DSGN): Can the Stock Really Move This High? - MSN
Galux Unveils a Study in AI-Powered De Novo Antibody Design for Multiple Therapeutic Targets - The Manila Times
Design Therapeutics (DSGN) Upgraded to Buy: Here's Why - MSN
ElevateBio taps Amazon’s genAI tools to design CRISPR therapeutics - Yahoo Finance
RBC Raises Price Target on Design Therapeutics to $5 From $4, Keeps Sector Perform, Speculative Risk - Marketscreener.com
Design Therapeutics (DSGN) to Release Earnings on Tuesday - Defense World
KODKodiak Sciences Inc. Latest Stock News & Market Updates - StockTitan
ALGSAligos Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Design Therapeutics provides corporate highlights, anticipated milestones - TipRanks
Design Therapeutics, Inc. SEC 10-K Report - TradingView
Design Therapeutics Initiates Phase 1 Trial for DT-216P2; Reports Progress and Financial Results for 2024 - Nasdaq
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results - Marketscreener.com
Design Therapeutics Clinical Programs Progress: FA Trial Launches, FECD Dosing Complete - StockTitan
Rhumbline Advisers Increases Stake in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
3 Reasons to Sell DVA and 1 Stock to Buy Instead - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
PSTV Rallies, TOVX Gears Up For VIRAGE Trial Data, Will AVTX's LOTUS Bloom? - RTTNews
2 Magnificent Warren Buffett Stocks That Make for Screaming Buys in March, and 1 to Avoid - The Globe and Mail
Design Therapeutics to Participate in Leerink's Global Healthcare Conference - The Manila Times
Clinical-Stage Biotech Design Therapeutics Gears Up for Key Investor Presentation at Leerink Conference - StockTitan
Operational definition of developmental and epileptic encephalopathies to underpin the design of therapeutic trials - Wiley Online Library
Seaport Therapeutics Presents New Meta-Analysis Examining Correlations Between Clinical Trial Design Factors and Placebo Response in Major Depressive Disorder Studies - Yahoo Finance
Can Astria's New HAE Drug Data Transform Treatment? Key Findings Revealed at Major Medical Congress - StockTitan
US Penny Stocks To Watch In February 2025 - simplywall.st
Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga
Why GCL Global Holdings Shares Are Trading Higher By Around 107%; Here Are 20 Stocks Moving Premarket - Benzinga India
Plant Defense Peptides: Exploring the Structure–Function Correlation for Potential Applications in Drug Design and Therapeutics - ACS Publications
Newleos Raises $93.5M to Advance Neuropsychiatric Cast-Offs from Roche - BioSpace
Terrain Biosciences emerges from stealth to enable faster therapeutics and vaccine development with better RNA - Morningstar
AI Proteins Appoints Philip E. Brandish, PhD as Chief Development Officer - Business Wire
Pliant Stock Crashes After Suspension of Idiopathic Pulmonary Fibrosis Study - BioSpace
Design Therapeutics, Inc. (NASDAQ:DSGN) Short Interest Up 8.1% in January - MarketBeat
AI-based predictive biology coming soon, Foresite’s Bajaj says - BioCentury
Design Therapeutics, Inc. (NASDAQ:DSGN) Position Increased by JPMorgan Chase & Co. - Defense World
Design Therapeutics: Not A Complete Washout Despite Setback - Seeking Alpha
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Breakthrough in Kidney Disease Treatment: Regulus Drug Shows Promising Results in Clinical Trial - StockTitan
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases - Yahoo Finance
Harness going after new target, FAN-1, in Huntington’s disease - BioWorld Online
Assenagon Asset Management S.A. Trims Stock Position in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Design Therapeutics, Inc. (NASDAQ:DSGN) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Ovid Therapeutics Inc. (NASDAQ:OVID) Position Cut by Assenagon Asset Management S.A. - Defense World
Assenagon Asset Management S.A. Buys New Stake in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Lululemon Athletica Inc. (NASDAQ:LULU) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Assenagon Asset Management S.A. Sells 782 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - Defense World
THC Therapeutics Has Completed the dHydronator(R) Consumer Model Design - ACCESS Newswire
디자인 테라 (DSGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):